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Abstract 
Background: Theoretically human embryonic stem cells (hESCs) have the capacity to self-renew and differentiate 
into all human cell types. Therefore, the greatest promise of hESCs-based therapy is to replace the damaged tissues of 
patients suffering from traumatic or degenerative diseases by the exact same type of cells derived from hESCs. Allo-
graft immune rejection is one of the obstacles for hESCs-based clinical applications. Human leukocyte antigen (HLA) II 
leads to CD4+ T cells-mediated allograft rejection. Hence, we focus on optimizing hESCs for clinic application through 
gene modification.
Results: Transcription activator-like effector nucleases (TALENs) were used to target MHC class II transactivator (CIITA) 
in hESCs efficiently. CIITA−/− hESCs did not show any difference in the differentiation potential and self-renewal capac-
ity. Dendritic cells (DCs) derived from CIITA−/− hESCs expressed CD83 and CD86 but without the constitutive HLA II. 
Fibroblasts derived from CIITA−/− hESCs were powerless in IFN-γ inducible expression of HLA II.
Conclusion: We generated HLA II defected hESCs via deleting CIITA, a master regulator of constitutive and IFN-γ 
inducible expression of HLA II genes. CIITA−/− hESCs can differentiate into tissue cells with non-HLA II expression. It’s 
promising that CIITA−/− hESCs-derived cells could be used in cell therapy (e.g., T cells and DCs) and escape the attack 
of receptors’ CD4+ T cells, which are the main effector cells of cellular immunity in allograft.
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Background
Since the first establishment of hESCs by Thomson’s 
group in 1998 [1], many therapy strategies based on 
hESCs have been attempted to cure human diseases. Nev-
ertheless, several major obstacles remain to be addressed 
before clinical applications of hESCs-based cells replace-
ment therapy, such as allograft immune rejection. Hence, 
we focus on generating hypoimmunogenic and univer-
sally compatible hESCs for clinical use, which can attenu-
ate the effect of T cell-mediated rejection.
The activation of T cells is based on two signals (TCR-
HLA signal and costimulatory signal). HLA molecules 
are encoded by a large gene family and divided into class 
I and II. Firstly, professional or non-professional antigen-
presenting cells (APCs) degrade proteins into peptides 
and then load these peptides onto HLA molecules. And 
then, TCRs of CD4+ and CD8+ T cells recognized the 
peptides presented by HLA II and HLA I, respectively. 
At the same time, those APCs must express a spectrum 
of costimulatory molecules (e.g., CD80 and CD86), 
which will interact with complementary molecules of T 
cells (e.g., CD28 and Cytotoxic T lymphocyte antigen 4 
(CTLA4)). Both TCR-HLA signal and costimulatory sig-
nal are required for activation of T cells [2]. Thus, if we 
inhibit either of them, T cells would not attack the allo-
grafts. We chose to delete HLA molecules. It has been 
proved that hESCs expressing CTLA4-immunoglobu-
lin fusion protein (CTLA4-Ig) and programmed death 
ligand-1 (PD-L1) can suppress the allogeneic immune 
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response by simultaneously disrupting the costimulatory 
pathway and activating the T cell inhibitory pathway [3, 
4]. This strategy is useful but not generally applicable. For 
example, T cells derived from hESCs can’t be activated 
with the expression of CTLA4-Ig and PD-L1. So it will 
limit the application of hESCs in clinic immunotherapy, 
such as hESCs-derived chimeric antigen receptor (CAR)-
T, an effective therapy in cancer treatment [5]. Moreover, 
unlike mice T cells, activated human T cells will express 
HLA II. So our strategy has an advantage to produce 
hypoimmunogenic and universally compatible CAR-T, 
and they can prevent the rejection mediated by recipi-
ents’ T cells. Furthermore, we can also derive DCs from 
those hESCs without HLA II. Though those DCs can’t 
present antigens normally, the CAR technique (CAR-
DCs) [6] and artificial HLA-peptide [7, 8] will let them be 
more specific and sensitive to the cancers.
HLA I molecules are found on the surface of each 
nucleated cells [9]. Constitutive HLA II molecules are 
expressed mainly on thymic epithelial cells and profes-
sional APCs, including DCs, B-lymphocytes, monocytes 
and macrophages. Under the stress of inflammatory 
cytokines (e.g., IFN-γ and TNF-α), nonprofessional APCs 
such as fibroblasts and epithelial cells can also express 
HLA II molecules, which are known as “induced HLA 
II” [10]. Each classical HLA I molecule structurally con-
sists of a polymorphic heavy chain (e.g., HLA-A, HLA-B 
and HLA-C), which binds to a same light chain β2M. 
Other group and our lab have knocked out β2M in hESCs 
and demonstrated the loss of HLA I molecules, which 
endowed hESCs with the capacity of avoiding the CD8+ 
T cells-mediated rejection [11, 12]. Those papers opti-
mized hESCs through HLA I deletion, and this strategy 
was easy to test because of the constitutive expression of 
HLA I in each nucleated cells [11–13]. So far, no report 
has demonstrated the generation of hESCs with the abil-
ity of differentiating to cells without constitutive and 
IFN-γ induced HLA II.
With conserved binding regions, HLA II genes are 
regulated by a same regulatory complex consists of three 
RFX factors (RFXAP, RFX5, RFXANK) and CIITA [14, 
15]. This complex regulates not only the genes encod-
ing classical HLA II molecules (HLA-DP, HLA-DQ and 
HLA-DR) but also the genes encoding accessory pro-
teins that are required for intracellular transportation 
and peptide loading of HLA II molecules, including the 
non-classical HLA II molecules (invariant chain (Ii), 
HLA-DM and HLA-DO) [16]. In some cases, tumor cells 
[17] and virus-infected cells [18, 19] will escape CD4+ T 
cells-mediated immune rejection via silencing the HLA 
II. Here using TALENs technique, we disrupted HLA II 
molecules of hESCs by knocking out CIITA—the master 
regulator of HLA II molecules [16, 20]. The main function 
of CIITA is HLA II regulation so they have almost same 
cellular distribution. CIITA does not bind DNA directly 
but interacts with other elements consisting of cyclic 
AMP response element-binding protein (CREB), nuclear 
factor Y complex (NF-Y) and RFX factors (RFX5, RFX-
ANK, RFXAP). Patients without functional CIITA are 
suffering from bare lymphocyte syndrome (BLS), which 
is characterized by the lack of expression of HLA II in tis-
sue cells [16]. CIITA−/− mice are also impaired in MHC 
class II-mediated allogeneic responses [20].
CIITA has four promoters, and they can regulate HLA 
II expression in a tissue-specific manner [16]. In order 
to target CIITA thoroughly, we designed TALENs in the 
communal exons (exon 2 and 3) of all transcripts. hESCs 
don’t express HLA II and CIITA in vitro even during the 
embryoid bodies (EBs) differentiation or IFN-γ induc-
tion [21]. We checked the constitutive and induced HLA 
II molecules on hESCs-derived DCs and fibroblasts, 
respectively. We found that the deletion of CIITA can 
decrease the constitutive and induced expression of HLA 
II molecules dramatically.
Results and discussion
Disruption of CIITA in hESCs by TALENs
In this study, we targetedly knockout CIITA in hESCs 
with TALENs, which have fewer off-target events than 
Cas9 and more maneuverable than ZFNs [22]. TALENs 
of CIITA were designed for exon 2 and exon 3 target-
ing. The most efficient TALEN pairs (2L2 and 2R2) were 
selected from 293T test and were used to target CIITA 
in X1 hESCs [23] (Fig. 1a). Both heterozygous (CIITA+/−) 
and homozygous (CIITA−/−) hESCs were obtained in one 
targeting round with the efficiency of 70  % (Fig.  1b, c). 
Potential off-targets were found by TAL Effector Nucleo-
tide Targeter 2.0 [24] and were checked by sequencing. 
No mutation was found in potential off-targets (Addi-
tional file 1: Table S1).
The pluripotency of CIITA targeted hESCs
The pluripotency of hESCs are necessary for its appli-
cation in cells replacement therapy. So we checked the 
pluripotency in established CIITA-targeted hESCs. 
Immunostaining showed that CIITA−/− hESCs were 
positive for Oct4, Nanog, Tra-1-60 and SSEA3 (Fig. 2a). 
When CIITA−/− hESCs were injected into non-obese dia-
betic/severe combined immune-deficient (NOD/SCID) 
mice, teratomas formed after 2  months, and tissues 
derived from three germ layers were observed in hema-
toxylin–eosin (HE) staining section (Fig. 2b). EBs derived 
from CIITA−/− hESCs were performed RT-PCR to show 
the expression of three germ layers markers (Fig.  2c). 
Moreover, both CIITA−/− and CIITA+/− hESCs had nor-
mal karyotypes (Fig. 2d). We used the normal karyotype 
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lines in the following experiments. Thus the targeted 
hESCs did not show any difference in pluripotency and 
karyotypes. So our study would be an attempt to estab-
lish clinical hESCs.
CIITA and HLA II expression in defined cells derived 
from CIITA targeted hESCs
Previous reports and our own experiments have pointed 
out that hESCs don’t express CIITA or HLA II, even 
when they are forming EBs or under IFN-γ induction 
[21]. Unfortunately, we transplant differentiated cells 
rather then hESCs into human body directly for the 
cells replacement therapy. Some tissue cells (e.g., profes-
sional APCs and thymic epithelial cells) have constitutive 
expression of HLA II molecules and some other tissue 
cells (e.g., fibroblasts and epithelial cells) have induced 
expression of HLA II molecules. In order to ensure the 
functional disruption of HLA II, we investigated both 
kinds of HLA II expression in defined types of cells 
derived from CIITA targeted hESCs.
Firstly, we tested IFN-γ inducible HLA II on hESCs-
derived fibroblasts with 5 days’ treatment of 500 U IFN-
γ. CCD-1079SK (CCD) cell line, a human fibroblast cell 
line, was used as a positive control. IFN-γ induction can 
increase the expression of β2M in tissue cells [11]. With-
out IFN-γ treatment, all cells showed low-level expres-
sion of HLA II genes (CIITA, DRA, DPA, DQA, Ii) and 
β2M. With IFN-γ treatment, β2M and CIITA mRNA 
increased in all groups as reported [11, 16] (Fig.  3a). 
Our CIITA targeting did not affect the transcription of 
CIITA as expected. After IFN-γ treatment, CIITA+/+ 
and CIITA+/− fibroblasts increased mRNA expression 
of HLA II genes (DRA, DPA, DQA, Ii) as CCD cells did 
(Fig.  3a). However, IFN-γ treated CIITA−/− fibroblasts 
didn’t increase mRNA expression of HLA II genes (DRA, 
DPA, DQA, Ii) obviously (Fig.  3a). It suggested that 
CIITA mRNA detected in IFN-γ treated CIITA−/− fibro-
blasts was dysfunctional and couldn’t be translated into 
a functional protein to regulate the expression of HLA 
II (Fig. 3a). It was proved by the following Western blot-
ting and Immunochemistry data (Fig. 3b, c). It also indi-
cated that CIITA+/− fibroblasts had a low level increase 
of CIITA and HLA II protein lagged behind the increase 
of mRNAs (Fig. 3b, c). FACS analysis of all groups dem-
onstrated that few cells expressed HLA II on cell sur-
face without IFN-γ induction. After IFN-γ induction, 
CCD and CIITA+/+ fibroblasts increased expression of 
HLA I and II dramatically. However, neither CIITA+/− 
nor CIITA−/− increased expression of HLA II obviously 
(Fig. 3d).
Secondly, we derived DCs from hESCs to test con-
stitutive HLA II expression. Focused on clinical using, 
we chose a protocol with definitive chemical compo-
sition media without serum, feeder or other animal 
Fig. 1 Disruption of CIITA in hESCs by TALENs. a Sequences on exon 2 of human CIITA for target by TALENs.b Alignment of the genomic sequences 
of mutants and wildtypes (wt) at the TALEN target site. The number of deleted (dashes) or inserted (letters in red) nucleotides compared with the wt 
sequences is indicated on the left of each sequence. c Efficiency of generation CIITA-deficient hESCs using TALENs in X1
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products [25]. DCs derived from hESCs express CD83 
and CD86 [25] (Fig.  4a, b). Compared with CIITA+/+ 
and CIITA+/− DCs, lower level of classical HLA II mol-
ecules (DRA, DQA and DPA) mRNA expression was 
found in CIITA−/− DCs dramatically (Fig.  4a). How-
ever, non-classical HLA II genes (Ii) did not show any 
difference in mRNA expression among them (Fig.  4a). 
Both classical HLA II genes (HLA-DP, HLA-DQ and 
HLA-DR) and non-classical HLA II genes (HLA-DM, 
HLA-DO, Ii) have a same specific regulatory module, 
which can be recognized by RFX-CIITA complex. Pre-
vious researches had shown that only HLA-DR expres-
sion was completely dependent on CIITA, which may 
cause the residual expression of other HLA II molecules 
Fig. 2 The pluripotency of CIITA targeted hESCs. a Immunostaining of pluripotent markers, Nanog, Oct4, SSEA3 and Tra-1-60 in CIITA−/− hESCs. b HE 
staining identified three germ layers [mesoderm (left), ectoderm (middle) and endoderm (right)] in teratomas formed from CIITA−/− hESCs. Scale bar 
100 μm. c RT-PCR analysis of differentiated markers expression in CIITA-targeted hESC-derived EBs. d Karyotype analysis of CIITA heterozygous and 
homozygous hESCs. Both groups had two samples been analyzed and no abnormal karyotype was found
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Fig. 3 CIITA and HLA Class II Expression in fibroblasts derived from CIITA targeted hESCs. a RT-PCR analysis of β2M, CIITA, HLA II (DRA, DQA, DPA) and 
Ii in hESCs-derived fibroblasts. They were treated with IFN-γ (500 U/ml) for 5 days. The control groups were IFN-γ free. All groups were compared 
with CIITA+/+ IFN-γfree group. Significance was assessed by a t test. The data are expressed as the mean ± SEM. n ≥ 3. *** p < 0.001, ** P < 0.01. 
Western blotting (b) and immunostaining (c) analysis of HLA II and CIITA proteins expression in fibroblasts (fibroblasts treated as mentioned above). 
Scale bar 100 μm. d FACS analysis of HLA I and II proteins expression on cell surface in fibroblasts (fibroblasts treated as mentioned above)
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in CIITA-targeted cells (Figs. 3a, 4a) [26, 27]. Obviously, 
Ii had different trends between DCs and fibroblasts, and 
it indicated a different regulatory pathway of Ii inde-
pendent of CIITA. The expression of Ii in IFN-γ induced 
fibroblasts and DCs may both depend mainly on CIITA, 
while DCs differentiation last such a long time to acti-
vate the substituted regulation pathway without CIITA. 
Fortunately Ii is encoding accessory proteins, which is 
required for peptide loading of HLA II molecules [16] 
and can’t rescue the loss of DRA, DPA and DQA on the 
cell surface (Figs. 3d, 4b).
We defined DCs with CD83 and CD86, and compared 
the percentage of HLA II+ cells in CD83+CD86+ DCs. 
PBM derived DCs showed high overlap of those three 
markers (Fig.  4b). CIITA−/− DCs only had 1.98  % HLA 
II+ cells while CIITA+/+ and CIITA+/− DCs had higher 
percentage of HLA II+ cells, 39.1 and 24.8 % respectively.
Conclusion
We established HLA II-deficient hESCs by disrupting 
CIITA successfully. Fibroblasts and DCs derived from 
those gene-modified hESCs showed defect in induced 
Fig. 4 HLA Class II Expression in DCs derived from CIITA targeted hESCs. a RT-PCR analysis of CD83, CD86, CD11c, DRA, DPA, DQA, Ii, CIITA, HLA-E and 
β2M in DCs derived from CIITA-targeted hESCs. All groups were compared with CIITA+/+ hESCs group. b FACS analysis of HLA II expression in DCs, 
which were defined by the co-expression of CD83 and CD86. And compare the percentage of HLA II+. Significance was assessed by a t test. The 
data are expressed as the mean ± SEM, n ≥3. ***P < 0.001, ** P < 0.01, * P < 0.05
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and constitutive expression of HLA II molecules, respec-
tively. It indicated that cells derived from CIITA−/− 
hESCs could escape from the attack of CD4+ T cells 
when transplanted into human body, because they were 
HLA II free. We combined β2M and CIITA deletion in 
hESCs and further transplant experiments should be 




hESCs were cultured and passaged as our previous 
paper described [11]. In brief, hESCs were cultured 
with the Irradiated CF1 feeder cells (3×104 cells/cm2) 
on the T25 flasks (Corning) coated with Matrigel (Bec-
ton–Dickinson). hESCs were maintained in DMEM/F12 
(Invitrogen) supplemented with 20  % knockout serum 
replacement (Invitrogen), 4  ng/mL basic fibroblast 
growth factor (bFGF; Invitrogen), 2 mmol/L l-glutamine 
(Invitrogen), 1  % nonessential amino acids (Invitrogen) 
and 0.1  mmol/L β-mercaptoethanol (Sigma-Aldrich). 
hESCs were passaged approximately once a week. Col-
lagenase IV was used to dissociate the cells from the 
feeders as cell clumps, which were dissociated to an 
appropriate size before being passaged onto newly pre-
pared feeder cells.
TALENs efficiency detection
TALENs for CIITA were designed to target exon2 (2L1: 
gctgaccccctgtgcct; 2L2: gaccccctgtgcctct; 2R1: ctccagcca 
ggtccatct; 2R2: tctccagccaggtccat) and exon3 (3L1: 
tcagcaggctgttgt; 3L2: tcagcaggctgttgtgt; 3R1: ccctggtc 
tcttcat; 3R2: aagcctccctggtctt; 3R3: aagcctccctggtct). 
The TALENs were constructed with FastTALE TALEN 
Assembly Kit (Sidansai), and their activities were con-
firmed in 293T cells as previous description [11]. The 
constructed TALENs were transfected into 293T cells 
and selected with 2  μg/ml puromycin (Sigma). The 
genomic DNA of 293T cells was harvested after selection. 
Then, PCR and sequencing were performed to examine 
the efficiency of the TALENs.
Generation of CIITA‑deficient hESCs
To prepare the cells for transfection, harvested hESCs 
were plated in six well plates coated with Matrigel in 
mTeSR™1 medium (Stemcell Technologies). On the fol-
lowing day the most efficient TALENs (2L2 and 2R2) 
plasmids and EGFP-Puro plasmid (Sidansai) (1:1:1) were 
transfected into hESCs by the FuGENE HD transfec-
tion reagent (Promega). We incubated the FuGENE HD 
Transfection Reagent/plasmids/Opti-MEM (Life Tech-
nologies) mixture (15 ul/6 ug/300 ul) for 15 min at room 
temperature, and then the mixture was added into the 
cell culture. Puromycin was added into media two days 
later. After selection with 0.5 μg/ml puromycin the sur-
vival colonies were dissociated into single cells using Try-
pLE (Invitrogen) and seeded onto CF1-coated plates at a 
density of 500 cells/cm2. Two weeks after passaging, the 
colonies derived from the single cells were transferred 
into freshly CF1-coated wells, and in parallel, a direct cell 
PCR kit was used to identify the mutants.
Teratomas formation and derivation of human fibroblasts 
from teratomas
hESCs were injected intramuscularly into 6–8  weeks 
NOD/SCID mice (approximately 5 ×  106 cells per site). 
After about 2  months, the tumors were processed for 
hematoxylin-eosin (HE) staining.
The fibroblast-like cells were also derived from terato-
mas [28]. Teratomas were cut into pieces with scissors 
and cultured in DMEM supplemented with 10 % serum, 
1 % Pen-Strep, and 50 uM β-mecaptoethanol. After sev-
eral passages, the adherent cells become homogenous 
and fibroblast-like cells. Cell morphological observa-
tion and RT-PCR were performed (Additional file 2: Fig-
ure S1a, b). Ten cell lines were established (3 for +/+; 3 
for +/–; 4 for −/−). And we analyzed some mesenchy-
mal stem cells markers in established cells lines (n  >  3) 
(Additional file  2: Figure  S1c). CCD and mesenchymal 
stem cells (MSC) were used as control. Those cell lines 
were more like fibroblasts. It showed that this method 
was reproducible in our experiments. All of the animal 
experiments were conducted in accordance with the 
Guide for the Care and Use of Animals for Research Pur-
poses and approved by the Zhejiang University Animal 
Care Committee.
Reverse Transcription‑PCR and Real‑Time PCR analysis
Total RNA was prepared using an RNeasy kit (Qiagen), 
which was then used as a template for real-time PCR 
(RT-PCR). RT-PCR was performed in an Eppendorf Mas-
tercycler® ep realplex real-time PCR system using SYBR 
Green-based PCR Master mix (TOYOBO). Standard 
curves were acquired for both the genes of interest and 
internal control (G3PD). The primers used are listed in 
Additional file 3: Table 1.
Immunochemistry
Immunochemistry was performed as previously 
described [29]. The primary antibodies used were anti-
Oct4 (1:100, Santa Cruz Biotechnology), anti-Nanog 
(1:150, Santa Cruz Biotechnology), anti-Tra-1-60 (1:150, 
Chemicon), anti-SSEA3 (Ascites, 1:400, Developmen-
tal Studies Hybridoma Bank), anti-CIITA (1:200, Santa 
Cruz Biotechnology) and anti-HLA DR+DP+DQ (1:200, 
Abcam) for staining.
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Western blotting
Protein extracts were obtained by lysing cells. Samples 
were fractionated by SDS-PAGE and transferred to pol-
yvinylidene-fluoride (PVDC) membrane. After blocking 
with 5  % milk in PBST (phosphate-buffered saline with 
0.1 % tween 20) for 1 h at room temperature, the mem-
branes were probed with the corresponding primary 
and secondary antibodies. And the following antibod-
ies were used: anti-HLA DR+DP+DQ (1:200, Abcam), 
anti-CIITA (1:200, Santa Cruz Biotechnology) and anti-
β-Actin (1:5000, HuanAn).
Derivation of human DCs from hESCs
We induced the differentiation of DCs from hESCs by 
step-wise growth factors induction in suspension cul-
ture of EBs as previously reported [25]. In the first 5 days, 
hESCs showed mesoderm specification in the X-VIVO™ 
15 medium (Lonza) supplemented with 1  mM sodium 
pyruvate, 1×  non-essential amino acids, 2  mM l-glu-
tamine, 50 mM 2-mercaptoethanol and the four growth 
factors, including recombinant human bone morpho-
genetic protein-4 (rhBMP-4; BD), recombinant human 
vascular endothelial growth factor (rhVEGF; R&D), 
recombinant human granulocyte-macrophage colony-
stimulating factor (rhGM-CSF; R&D) and recombi-
nant human stem cell factor (rhSCF; R&D). From day 6 
to day 10, rhBMP-4 was removed, and the cells became 
hematopoietic stem cells (HSCs). From day 11 to day15, 
rhVEGF was removed and HSCs turned into common 
myeloid progenitors (CMP). From day 16 to day 20, 
rhSCF was removed and monocyte-like cells appeared 
and accumulated gradually as DC precursors. DC pre-
cursors will become immature DCs (iDCs) with the treat-
ment of rhGM-CSF and recombinant human Interleukin 
4 (rhIL-4; R&D) in the next 4–6  days. The maturation 
of DCs needed further incubation for 1–2 days with the 
mixed factors, including rhGM-CSF, recombinant human 
Interleukin-1 beta (rhIL1-β; R&D), recombinant human 
Interferon gamma (rhIFN-γ; R&D), Prostaglandin E2 
(PGE-2; Sigma) and recombinant human Tumor necrosis 
factor alpha (rhTNF-α; R&D).
Fluorescence‑activated cell sorting
Cells were dissociated with TrypLE and were stained for 
30 min at 4 °C in 100 μL of 0.5 % FBS in PBS containing 
an appropriate dilution of PE, FITC, APC or PE-CY™7-
conjugated antibody. Primary antibodies included human 
CD83, CD86, HLA II and HLA I (BD Biosciences). The 
sample measurement was performed on a BD FACS-
Calibur flow cytometer system, and the analysis was per-
formed using FlowJo software (Tree Star, Ashland, OR).
Statistical analysis
All of the data are represented as the mean ± SEM. The 
data were analyzed statistically using GraphPad Prism 5.1 
(GraphPad Software Inc., USA). All performance variants 
were analyzed by the unpaired Student’s T test. State-
ments of significance were based on *P < 0.05 unless oth-
erwise stated.
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